Ceruvia Lifesciences received three U.S. patent allowances and a European Unitary Patent grant covering BOL-148, a non-hallucinogenic LSD analogue being developed for cluster headache.

The U.S. allowances cover BOL-148’s proprietary crystalline form, 2-Br-LSD HBr, and two high-purity manufacturing processes, including routes starting from bromocriptine. Ceruvia also obtained a European Unitary Patent for its preferred salt form, while the Canadian Patent Office deemed its corresponding application allowable.